Erratum: Impaired proinsulin processing is a characteristic of transplanted islets (American Journal of Transplantation (2009) 9 (2119-2125) (doi: 10.1111/j.1600-6143.2009.02740.x));Impaired proinsulin processing is a characteristic of transplanted islets

American Journal of Transplantation

Volumn 9, Issue 9, 2009, Pages 2119-2125

  Klimek, A M ^a   Soukhatcheva, G ^a   Thompson, D M ^b   Warnock, G L ^a   Salehi, M ^c   Rilo, H ^c   D'Alessio, D ^c   Meneilly, G S ^b   Panagiotopoulos, C ^d   Verchere, C B ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Department of Medicine ^*

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Allograft function; Autologous transplantation; Beta cell; Clinical islet transplantation; Insulin secretion; Islet transplantation

Indexed keywords

C PEPTIDE; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; INSULIN; METFORMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIOGLITAZONE; PROINSULIN; RAPAMYCIN; TACROLIMUS;

ADULT; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOASSAY; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

EID: 69149100781     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03435.x     Document Type: Erratum

References (34)

1. Shapiro AM, Ricordi C, Hering BJ et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006 355 : 1318 1330.
2. Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005 54 : 2060 2069.
3. Rickels MR, Kamoun M, Kearns J, Markmann JF, Naji A. Evidence for allograft rejection in an islet transplant recipient and effect on beta-cell secretory capacity. J Clin Endocrinol Metab 2007 92 : 2410 2414.
4. Giuliani M, Moritz W, Bodmer E et al. Central necrosis in isolated hypoxic human pancreatic islets: Evidence for postisolation ischemia. Cell Transplant 2005 14 : 67 76.
5. Smith RN, Kent SC, Nagle J et al. Pathology of an islet transplant 2 years after transplantation: Evidence for a nonimmunological loss. Transplantation 2008 86 : 54 62.
6. Davalli AM, Ogawa Y, Ricordi C, Scharp DW, Bonner-Weir S, Weir GC. A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation 1995 59 : 817 820.
7. Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes 2002 51 : 66 72.
8. Carlsson PO, Palm F, Mattsson G. Low revascularization of experimentally transplanted human pancreatic islets. J Clin Endocrinol Metab 2002 87 : 5418 5423.
9. Polastri L, Galbiati F, Bertuzzi F et al. Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. Acta Diabetol 2002 39 : 229 233.
10. Reffet S, Thivolet C. Immunology of pancreatic islet transplantation. Diabetes Metab 2006 32 (5 Pt 2 523 526.
11. Tamura K, Fujimura T, Tsutsumi T et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. Transplant Proc 1995 27 : 357 361.
12. Rickels MR, Schutta MH, Markmann JF, Barker CF, Naji A, Teff KL. {beta}-Cell function following human islet transplantation for type 1 diabetes. Diabetes 2005 54 : 100 106.
13. Luzi L, Hering BJ, Socci C et al. Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus. J Clin Invest 1996 97 : 2611 2618.
14. Luzi L. Metabolic strategies to predict and improve intrahepatic islet graft function. J Mol Med 1999 77 : 49 56.
15. Steiner DF, Rouille Y, Gong Q, Martin S, Carroll R, Chan SJ. The role of prohormone convertases in insulin biosynthesis: Evidence for inherited defects in their action in man and experimental animals. Diabetes Metab 1996 22 : 94 104.
16. Smeekens SP, Montag AG, Thomas G et al. Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3. Proc Natl Acad Sci USA 1992 89 : 8822 8826.
17. Furuta M, Carroll R, Martin S et al. Incomplete processing of proinsulin to insulin accompanied by elevation of des-31,32 proinsulin intermediates in islets of mice lacking active PC2. J Biol Chem 1998 273 : 3431 3437.
18. Zhu X, Orci L, Carroll R, Norrbom C, Ravazzola M, Steiner DF. Severe block in processing of proinsulin to insulin accompanied by elevation of des-64,65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc Natl Acad Sci U S A 2002 99 : 10299 10304.
19. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 1997 46 : 1725 1732.
20. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY. Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes 1995 44 : 173 179.
21. Larsson H, Ahren B. Relative hyperproinsulinemia as a sign of islet dysfunction in women with impaired glucose tolerance. J Clin Endocrinol Metab 1999 84 : 2068 2074.
22. Porte D Jr., Kahn SE. Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction? Diabetes 1989 38 : 1333 1336.
23. Warnock GL, Meloche RM, Thompson D et al. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs. best medical therapy in type 1 diabetes mellitus. Arch Surg 2005 140 : 735 744.
24. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987 30 : 698 702.
25. Smith SA, Porter LE, Biswas N, Freed MI. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. J Clin Endocrinol Metab 2004 89 : 6048 6053.
26. Ryan EA, Lakey JR, Paty BW et al. Successful islet transplantation: Continued insulin reserve provides long-term glycemic control. Diabetes 2002 51 : 2148 2157.
27. Leahy JL, Halban PA, Weir GC. Relative hypersecretion of proinsulin in rat model of NIDDM. Diabetes 1991 40 : 985 989.
28. Dmitrewski J, Krentz AJ, Mayer AD et al. Metabolic and hormonal effects of tacrolimus (FK506) or cyclosporin immunosuppression following renal transplantation. Diabetes Obes Metab 2001 3 : 287 292.
29. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004 21 : 568 576.
30. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 27 : 2628 2635.
31. Davalli AM, Maffi P, Socci C et al. Insights from a successful case of intrahepatic islet transplantation into a type 1 diabetic patient. J Clin Endocrinol Metab 2000 85 : 3847 3852.
32. McDonald CG, Ryan EA, Paty BW et al. Cross-sectional and prospective association between proinsulin secretion and graft function after clinical islet transplantation. Transplantation 2004 78 : 934 937.
33. Fiorina P, Vergani A, Petrelli A et al. Metabolic and immunological features of the failing islet-transplanted patient. Diabetes Care 2008 31 : 436 438.
34. Katz AI, Rubenstein AH. Metabolism of proinsulin, insulin, and C-peptide in the rat. J Clin Invest 1973 52 : 1113 1121.